Company Insider Sells 1,230 Shares of $SDGR

Robert Lorne Abel, identified as the See Remarks representative of the company $SDGR, recently divested 1,230 shares on 02-09-2026, resulting in an estimated transaction value of $16,617. This sale constituted roughly 6.0% of their holdings in this specific class of stock, leaving them with a remaining ownership of 19,385 shares of this type of $SDGR stock.

Over the past 6 months, there have been two instances of insider trading involving $SDGR stock by company insiders, with both transactions reflecting sales rather than purchases. The Chief Medical Officer, Margaret Dugan, previously sold 1,395 shares of $SDGR stock for an approximate value of $29,387, while Robert Lorne Abel, the See Remarks representative, sold 1,230 shares for a total sum of $16,617.

Tracking the activities of hedge funds related to $SDGR stock reveals noteworthy changes in holdings among institutional investors. In the most recent quarter, 100 institutional investors opted to increase their stake in $SDGR, whereas 128 reduced their positions. Notable adjustments in investment portfolios include UBS AM, a distinct business unit of UBS Asset Management Americas LLC, augmenting their holdings by 3,192,038 shares (+93.5%) in Q3 2025, valued at approximately $64,032,282. Conversely, Cadian Capital Management, LP decided to divest all 3,045,952 shares (-100.0%) from their holdings during the same quarter, amounting to an estimated $61,101,797.

During the third quarter of 2025, $SDGR reported revenues of $54.3 million, reflecting a substantial increase of 53.94% compared to the corresponding period in the previous year. For a comprehensive view of financial data relating to $SDGR, interested parties can access relevant information on Quiver Quantitative’s dedicated $SDGR stock page.

Analyst ratings for $SDGR over recent months indicate a positive sentiment among Wall Street analysts, with three firms issuing buy ratings for the stock. There have been no sell ratings reported. Notable recommendations include a “Buy” rating from TD Cowen on 01/08/2026, a similar rating from B of A Securities on 12/15/2025, and an “Overweight” rating from Keybanc on 10/08/2025. For an extensive analysis of analyst ratings and target prices concerning $SDGR, individuals can refer to Quiver Quantitative’s $SDGR forecast page.

Multiple analysts have recently provided price targets for $SDGR, with a median target of $21.5 among six analysts who have weighed in within the last six months. Noteworthy projections include Scott Schoenhaus from Keybanc setting a target price of $25.0 on 01/08/2026, Brendan Smith from TD Cowen setting a target price of $24.0 on the same date, and Michael Yee from UBS targeting $18.0 on 01/07/2026. Other analysts from respected firms such as B of A Securities, Goldman Sachs, and Morgan Stanley have also issued their respective price targets.

It is essential to note that this article is intended for informational purposes and does not constitute financial advice. Interested individuals should consult Quiver Quantitative’s disclaimers for further information and clarification.